Psychedelic Therapy Safety: Patient Screening, Contraindications, and Risk Factors
About This Video
As legal psilocybin access expands across Oregon and Colorado, and as underground facilitation continues in all 50 states, rigorous patient screening has become one of the highest-stakes clinical skills in the psychedelic medicine field. This Psychedelic Medicine Association webinar covers the full clinical screening protocol used in regulated settings — who psilocybin is safe for, who it is contraindicated for, and the significant gray areas in between.
The absolute contraindications are clear and non-negotiable. Personal or first-degree family history of schizophrenia, schizoaffective disorder, or bipolar I disorder are hard contraindications in every clinical setting — these conditions involve baseline disruptions in dopaminergic and serotonergic function that psilocybin can dramatically worsen. The video explains the mechanism: psilocybin's 5-HT2A agonism can trigger psychotic breaks in vulnerable individuals, and the neurological basis for familial risk is well-established. A family history of psychosis is a risk factor even in the absence of personal diagnosis.
Lithium is covered in detail as a hard medication contraindication — the combination has been associated with seizures in multiple case reports. The serotonin syndrome risk with MAOIs is also reviewed: psilocybin is metabolized by MAO enzymes, and MAOIs can dramatically potentiate effects to dangerous levels. The video advises any facilitator who hears a client is on an MAOI to require medical clearance before any session.
The nuanced gray areas are the most valuable content: cardiovascular risk (psilocybin acutely raises heart rate and blood pressure — managed risk in most adults, but requires cardiologist clearance for uncontrolled hypertension, recent cardiac events, or arrhythmia history), active suicidality without adequate safety planning, recent major life destabilization, and inadequate social support for integration.
Screening protocols from Oregon's OHA-licensed program are presented as a clinical model: the three-question PTSD screen, the Columbia Suicide Severity Rating Scale, the standardized family history psychiatric questionnaire, and the required medication review.
Key Takeaways
- Absolute contraindications: personal or first-degree family history of schizophrenia, schizoaffective disorder, or bipolar I disorder. These are non-negotiable in all clinical settings.
- Lithium and MAOIs are hard medication contraindications — lithium increases seizure risk; MAOIs can potentiate psilocybin to dangerous levels.
- Cardiovascular risk is a managed contraindication: psilocybin raises heart rate and blood pressure acutely — uncontrolled hypertension, recent cardiac events, and arrhythmias require cardiologist clearance before sessions.
- Active suicidality without an adequate safety plan is a contraindication even though psilocybin is being studied for suicidality — clinical trial enrollment requires safety planning, not just SI screening.
- Oregon OHA's required screening battery (Columbia SSRS, family psychiatric history, medication review) is a replicable model for all facilitators in legal and underground settings.
Dive Deeper
Continue exploring this topic on LearnShrooms: